Rousselot has announced that it will debut the positive results of its first clinical study on Nextida GC at SupplySide West 2024.
The collagen peptide-based nutraceutical is designed to support the body's metabolic balance, and has been shown to be efficacious in the trial.
During the study period, it was identified that both a 5 and 10g dose of Nextida GC could significantly lower post-meal glucose spikes in healthy adults.
This trend was seen when adults consumed the functional ingredient 30 minutes before a meal.
Notably, taking the collagen peptide nutraceutical reduced the blood glucose spike observed after a meal by 42% on average.
Catch up with Rousselot at SSW 2024
This year, Rousselot will be the official sponsor for glucose management, meaning that the company's team of experts will be delivery two presentations on the hot topic.
Dr Janne Prawitt, Rousselot's Scientific Director of Health & Nutritio — joined by Dr Mariette Abrahams, CEO & Founder of Qina — will discuss metabolic health and how Nextida GC fits into the picture on Wednesday October 30 at 12–13:00 at the South Pacific Ballroom D.
As well as this, Dr Prawitt will share insights into Nextida GC's first clinical trial at the Supplier Presentation Theatre from 11–11:20 on Thursday, October 31.
Attendees to SupplySide West 2024 will also be able to speak to Rousselot's experts at booth 5641.
Visitors will also have the opportunity to sample Nextida GC, as well as discuss the company's other collagen peptide solution, Peptan — which is designed for beauty from within applications.
Rousselot's Executive Vice President, Jeroen Colpaert, commented: “We’re immensely excited to take our new step toward decoding the collagen molecule with the release of this first study,”
“With new science supporting our ingredient’s potential for post-meal glucose metabolism in healthy individuals, we are continuing our commitment to offering the health and wellness industry evidence-based solutions that expand what we know about collagen.”
